AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16651305
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) at a dose of 12.5 mg/kg every 12 hours for 6 months
Trial: 12792354
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg once daily for 14 days)
Trial: 10981801
Drug: Nicardipine in
RxNorm normalized name: nicardipine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine in an aqueous gel vehicle
Trial: 1582603
Drug: Glucose based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose based ORS plus food from the beginning of treatment (group B)
Trial: 1582603
Drug: Rice based
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice based ORS plus food from start of therapy (group D)
Trial: 6375979
Drug: Fluorometholone acetate
RxNorm normalized name: Fluorometholone Acetate
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorometholone acetate ophthalmic suspension
Trial: 6375979
Drug: Dexamethasone sodium
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium phosphate ophthalmic solution
Trial: 30059750
Drug: Adaptive servo-ventilation
RxNorm normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adaptive servo-ventilation (ASV) with optimal medical therapy (OMT)
Trial: 25441855
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment with elastic bandage
Trial: 18583576
Drug: Montelukast 4
RxNorm normalized name: montelukast 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4 mg/day
Trial: 18583576
Drug: Montelukast 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 8 mg/day
Trial: 12047489
Drug: Monosodium (L)-glutamate
RxNorm normalized name: Monosodium Glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium (L)-glutamate (10 g)
Trial: 9952072
Drug: Panamesine (PAN)
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Panamesine (PAN) 90 mg/day
Trial: 9952072
Drug: Panamesine (PAN)
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Panamesine (PAN) 30 mg
Trial: 2160354
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (750 mg)
Trial: 6680021
Drug: Cyclical levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical levamisole treatment (150 mg daily for 3 days repeated after a gap of 2 weeks) in addition to standard DDS treatment
Trial: 6680021
Drug: Standard DDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DDS treatment and placebo
Trial: 6680021
Drug: Cyclical levamisole
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical levamisole treatment
Trial: 31662536
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of platinum agents (PTs)
Trial: 31662536
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of platinum agents (PTs) or switching to non-platinum agents
Trial: 30239425
Drug: Dispersible FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible FDC tablet of abacavir 150 mg/dolutegravir 10 mg/lamivudine 75 mg administered in high- or zero-mineral content water, either immediately or after a 30-minute delay.
Trial: 30239425
Drug: Nondispersible dolutegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondispersible dolutegravir 10 mg tablets plus nondispersible abacavir 600 mg/lamivudine 300 mg tablet administered with zero-mineral content water.
Trial: 27426855
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin 75 mg and heparin 5000 IU subcutaneous every 12 h
Trial: 27426855
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin and heparin
Trial: 24299019
Drug: Atorvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin plus omega-3 fatty acid ethyl esters (4 g/day)
Trial: 17823519
Drug: Daivobet/Dovobet/Taclonex (calcipotriol/betamethasone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daivobet/Dovobet/Taclonex (calcipotriol/betamethasone) once daily
Trial: 17823519
Drug: Non-fix calcipotriol/betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fix calcipotriol/betamethasone combination (morning/evening)
Trial: 1376197
Drug: Operative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative and nonoperative treatment options based on prostate size
Trial: 1376197
Drug: Interactive video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive video disc for explaining treatment options
Trial: 3975120
Drug: High-dose phototherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose phototherapy (12 microW/cm2/nm)
Trial: 3975120
Drug: Low-dose phototherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose phototherapy (6 microW/cm2/nm)
Trial: 23279372
Drug: sCD30 concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCD30 concentration ≥40.3 U/ml on day 14
Trial: 23279372
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of steroids
Trial: 21995804
Drug: Paramedic cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paramedic cooling during CPR using rapid infusion of ice-cold normal saline (4 °C, 20-40 mL/kg to a maximum of 2 litres)
Trial: 21995804
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment during CPR
Trial: 18812677
Drug: Low-dose carperitide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carperitide (0.01-0.05 microg x kg(‐1 ) x min(‐1)) for 72 hours
Trial: 16860048
Drug: Advance provision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advance provision of emergency contraception (2 x 0.75 mg levonorgestrel pills - Plan B)
Trial: 10988110
Drug: Pamidronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (30 mg intravenously every 3 months) with vitamin D (800 IU/d) and calcium (1 g/d)
Trial: 10988110
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (800 IU/d) and calcium (1 g/d) alone (Control)
Trial: 1291309
Drug: Clindamycin 150
RxNorm normalized name: clindamycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 150 mg every 6 h for seven days
Trial: 1291309
Drug: Phenoxymethylpenicillin 1
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 1 g every 12 h for seven days
Trial: 28055000
Drug: Pharmacological approaches
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological approaches (e.g., step‐up/down; self‐management; simplified regimen) and non‐pharmacological approaches (e.g., trigger management, education, social support; inhaler technique).
Trial: 26948284
Drug: 49-mg p-synephrine
RxNorm normalized name: synephrine
DrugBank: Synephrine (DB09203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 49-mg p-synephrine
Trial: 9431375
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir followed by oral acyclovir (10 mg/[kg.d] for 2 weeks, then 800 mg/m2 four times daily for 50 weeks)
Trial: 9431375
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir alone (10 mg/[kg.d] for 2 weeks)
Trial: 9431375
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir followed by oral acyclovir
Trial: 3014851
Drug: Suloctidil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suloctidil (200 mg 3 times daily)
Trial: 14712432
Drug: Daily hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hemodialysis (6 times/week)
Trial: 2167820
Drug: Aluminium citrate
RxNorm normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminium citrate (Al‐cit) treatment group, injected with 120 mg Al/year for five years
Trial: 7028636
Drug: Trimethoprim/sulphadiazine (4/16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 3 days
Trial: 7028636
Drug: Trimethoprim/sulphadiazine (4/16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulphadiazine (4/16 mg/kgBW/day in two doses) for 10 days
Trial: 28545589
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (5 g fructooligosaccharides mixed in lactose-free milk)
Trial: 28545589
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including low FODMAP ONS and positive control)
Trial: 19640734
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic agent (prilocaine 2%) plus 500 microg nitroglycerin (group A)
Trial: 19640734
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic agent (prilocaine 2%) (group B)
Trial: 11094579
Drug: i.v. ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ondansetron 4 mg (control)
Trial: 11094579
Drug: i.v. ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ondansetron 4 mg and cyclizine 50 mg (combination)
Trial: 3550214
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg 6 hr‐1)
Trial: 3550214
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg day‐1) with prazosin
Trial: 3550214
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg day‐1) with prazosin and captopril (25 mg 6 hr‐1)
Trial: 3550214
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg day‐1) alone
Trial: 28961803
Drug: PF‐00547659 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐00547659 22.5 mg
Trial: 28961803
Drug: PF‐00547659 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐00547659 75 mg
Trial: 28961803
Drug: PF‐00547659 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐00547659 225 mg
Trial: 26778925
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (>3 g/kg/day)
Trial: 26778925
Drug: Normal (habitual)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal (habitual) diet (2.6 ± 0.8 g/kg/day)
Trial: 25246821
Drug: Gadoxetic acid
RxNorm normalized name: Gadoxetic acid
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoxetic acid injection at 0.5 mL/s (n = 50)
Trial: 25246821
Drug: Gadoxetic acid
RxNorm normalized name: Gadoxetic acid
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoxetic acid injection at 1 mL/s (n = 51)
Trial: 23810267
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention addressing individual needs related to asthma control, inhaler technique, and medication adherence
Trial: 20971961
Drug: Nefopam 20
RxNorm normalized name: nefopam 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 20 mg IV over 30 minutes
Trial: 20971961
Drug: Nefopam 20
RxNorm normalized name: nefopam 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 20 mg IV over 30 minutes (healthy volunteers)
Trial: 18311576
Drug: Annual physical
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual physical examination, neck ultrasonography, and serum thyroid-stimulating hormone (TSH) measurement for patients undergoing thyroid lobectomy.
Trial: 15765200
Drug: AQUANOVA solubilisate
RxNorm normalized name: mercurius solubilis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AQUANOVA solubilisate (100 IU alpha-tocopheryl acetate and 400 mg crystalline vitamin C) in the form of vitaminized gummi bears
Trial: 15765200
Drug: Reference products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference products (conventional preparations)
Trial: 1578626
Drug: Scopolamine butylbromide
RxNorm normalized name: Scopolamine butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine butylbromide (0.2 mg.kg-1)
Trial: 1578626
Drug: Scopolamine butylbromide
RxNorm normalized name: Scopolamine butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine butylbromide (0.4 mg.kg-1)
Trial: 4092801
Drug: 2.5% indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% indomethacin solution applied 1 hour before UVB irradiation
Trial: 29128649
Drug: In-person Present‐Centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person Present‐Centered Therapy (PCT)
Trial: 25005045
Drug: Ringerfundin® solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringerfundin® solution
Trial: 25005045
Drug: Glucose/potassium‐based balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose/potassium‐based balanced crystalloid solution
Trial: 19128589
Drug: Amikacin therapy
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin therapy
Trial: 12946545
Drug: Ketotifen ophthalmic
RxNorm normalized name: ketotifen ophthalmic
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketotifen ophthalmic solution (0.025%)
Trial: 12946545
Drug: Desloratadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine (5 mg tablets)
Trial: 12946545
Drug: Ketotifen ophthalmic
RxNorm normalized name: ketotifen ophthalmic
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketotifen ophthalmic solution
Trial: 12946545
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (ketotifen and desloratadine)
Trial: 10644288
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg once in the evening)
Trial: 10644288
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microg [2 puffs] twice daily)
Trial: 1362432
Drug: Somatostatin (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (continuous infusion of 250 micrograms/h for 5 days plus daily bolus administration of 250 micrograms)
Trial: 30326906
Drug: Self-management exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management exercise program (5 sessions of 1.5 hours each) + information booklet + 18 sessions of spa therapy treatment (1 hour each)
Trial: 30326906
Drug: Information booklet
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information booklet + 18 sessions of spa therapy treatment (1 hour each)
Trial: 30326906
Drug: Information booklet
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information booklet + spa therapy
Trial: 22166557
Drug: Balapiravir 500,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balapiravir 500, 1000, or 1500 mg twice daily plus peginterferon alfa-2a (40KD)/ribavirin
Trial: 22166557
Drug: Balapiravir/peginterferon alfa-2a/ribavirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balapiravir/peginterferon alfa-2a/ribavirin combination
Trial: 20531106
Drug: Enema Casen
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enema Casen (250 ml)
Trial: 20531106
Drug: Fleet Enema
RxNorm normalized name: Fleet Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleet Enema (133 ml)
Trial: 18549372
Drug: In-clinic rescue
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-clinic rescue therapy (maximum of 2 visits per month)
Trial: 18549372
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (optimal self‐administered medical therapy)
Trial: 18549372
Drug: In-clinic rescue
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-clinic rescue therapy
Trial: 15909441
Drug: Zinc paste
RxNorm normalized name: ZINC PASTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc paste compound
Trial: 12543286
Drug: Elevated chromogranin
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated chromogranin A level (cutoff, 24 ng/mL)
Trial: 31129930
Drug: ASP2205 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP2205 10 mg
Trial: 31129930
Drug: ASP2205 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP2205 60 mg
Trial: 24108780
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (400 U of EV71 antigen)
Trial: 15592213
Drug: Bionator therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionator therapy
Trial: 11115338
Drug: Bile leakage
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile leakage test (injection of isotonic sodium chloride solution through the cystic duct)
Trial: 7662225
Drug: bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol (10 mg/day)
Trial: 7662225
Drug: verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: verapamil SR (240 mg/day)
Trial: 322827
Drug: Live-attenuated A/Hong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated A/Hong Kong/68 (H3N2) influenza vaccine
Trial: 31977858
Drug: Vicagrel 40
RxNorm normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicagrel 40 to 75 mg
Trial: 28187226
Drug: Calcifediol (25D3)
RxNorm normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcifediol (25D3) 20 μg/d
Trial: 21755327
Drug: n‐3 PUFA‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFA‐enriched tomato juice (500 mL daily, providing 250 mg of EPA and DHA)
Trial: 17582564
Drug: Ty21a live
RxNorm normalized name: Salmonella typhi Ty21a live antigen
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a live oral typhoid vaccine (2 doses in Norte, 3 doses in Occidente)
Trial: 17582564
Drug: Ty21a live
RxNorm normalized name: Salmonella typhi Ty21a live antigen
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a live oral typhoid vaccine (pooled analysis)
Trial: 11588454
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg iv omeprazole bolus injection (arm I)
Trial: 11588454
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg bolus followed by 8 mg/hr continuous infusion (arm II)
Trial: 31693299
Drug: Differential fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differential fractional excretion of sodium (FeNa) derived from a morning void collection
Trial: 27584715
Drug: Matrix therapy
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix therapy agent (ReGeneraTing Agent [RGTA])
Trial: 21652150
Drug: Intranasal spray
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray of oxytocin
Trial: 16245966
Drug: Brinzolamide twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brinzolamide twice-daily
Trial: 16245966
Drug: Dorzolamide three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide three times daily (Control)
Trial: 12076696
Drug: Fluconazole 50
RxNorm normalized name: fluconazole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 50 mg once daily for 7-14 days
Trial: 12076696
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 0.5 g thrice daily for 7-14 days
Trial: 9527195
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 30 g alpha‐KG/hour after the operation
Trial: 7608318
Drug: Eptastigmine 10
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptastigmine 10 mg
Trial: 7608318
Drug: Eptastigmine 30
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eptastigmine 30 mg